PMID- 30059665
OWN - NLM
STAT- In-Data-Review
LR  - 20180907
IS  - 1090-2422 (Electronic)
IS  - 0014-4827 (Linking)
VI  - 371
IP  - 1
DP  - 2018 Oct 1
TI  - Modulating SIRT1 activity variously affects thymic lymphoma development in mice.
PG  - 83-91
LID - S0014-4827(18)30593-7 [pii]
LID - 10.1016/j.yexcr.2018.07.043 [doi]
AB  - SIRT1 is a protein deacetylase with a broad range of biological functions, many
      of which are known to be important in carcinogenesis, however much of the
      literature regarding the role of SIRT1 in cancer remains conflicting. In this
      study we assessed the effect of SIRT1 on the initiation and progression of thymic
      T cell lymphomas. We employed mouse strains in which SIRT1 activity was absent or
      could be reversibly modulated in conjunction with thymic lymphoma induction using
      either the N-nitroso-N-methylurea (NMU) carcinogenesis or the
      nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) transgene. Decreased SIRT1
      activity reduced the development of thymic lymphomas in the NMU-treated mice but 
      was permissive for the formation of lung adenomas. Conversely, in the NPM-ALK
      transgenic mice, decreased SIRT1 activity had a modest promoting effect in the
      development of thymic lymphomas. The results of the work presented here add to
      the growing body of evidence that sirt1 is neither an outright oncogene nor a
      tumor suppressor. These opposing results in two models of the same disease
      suggest that the influence of sirt1 on carcinogenesis may lie in a role in tumor 
      surveillance.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Clark-Knowles, Katherine V
AU  - Clark-Knowles KV
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada. Electronic address: kaclark@ohri.ca.
FAU - Dewar-Darch, Danielle
AU  - Dewar-Darch D
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada. Electronic address: ddewar@ohri.ca.
FAU - Jardine, Karen E
AU  - Jardine KE
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada. Electronic address: kjardine@ohri.ca.
FAU - Coulombe, Josee
AU  - Coulombe J
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada. Electronic address: jcoulombe@ohri.ca.
FAU - Daneshmand, Manijeh
AU  - Daneshmand M
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada. Electronic address: mdaneshmand@ohri.ca.
FAU - He, Xiaohong
AU  - He X
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada. Electronic address: xhe@ohri.ca.
FAU - McBurney, Michael W
AU  - McBurney MW
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa,
      Canada; Department of Medicine, University of Ottawa, Ottawa, Canada; Department 
      of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa,
      Canada. Electronic address: mmcburney@ohri.ca.
LA  - eng
PT  - Journal Article
DEP - 20180727
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
OTO - NOTNLM
OT  - Cancer
OT  - Lymphoma
OT  - Oncogene
OT  - SIRT1
OT  - Thymus
EDAT- 2018/07/31 06:00
MHDA- 2018/07/31 06:00
CRDT- 2018/07/31 06:00
PHST- 2018/01/15 00:00 [received]
PHST- 2018/05/25 00:00 [revised]
PHST- 2018/07/26 00:00 [accepted]
PHST- 2018/07/31 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
PHST- 2018/07/31 06:00 [entrez]
AID - S0014-4827(18)30593-7 [pii]
AID - 10.1016/j.yexcr.2018.07.043 [doi]
PST - ppublish
SO  - Exp Cell Res. 2018 Oct 1;371(1):83-91. doi: 10.1016/j.yexcr.2018.07.043. Epub
      2018 Jul 27.